STOCK TITAN
  1. Home
  2. News
  3. AMRX

Amneal Pharmaceuticals, Inc. - AMRX STOCK NEWS

Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a leading global pharmaceutical company headquartered in Bridgewater, NJ. Amneal develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products across the United States, India, and Ireland. With a commitment to providing affordable medicines, Amneal operates through three key segments: Generics, Specialty, and AvKARE.

Generics Segment: This segment focuses on producing a wide range of dosage forms and delivery systems, including injectables and biosimilars, contributing significantly to the company's revenue. The Generics segment is dedicated to expanding across complex product categories and therapeutic areas, ensuring patients have access to vital medications.

Specialty Segment: Amneal's Specialty segment promotes proprietary branded pharmaceuticals targeting central nervous system and endocrine disorders. The segment has a growing portfolio of branded pharmaceuticals with a pipeline focused on addressing unmet medical needs, demonstrating the company's commitment to innovation.

AvKARE Segment: This segment distributes pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution. AvKARE focuses on offering consistent care and pricing to qualified entities, enhancing access to essential medicines for governmental and institutional markets.

Recently, Amneal has achieved significant milestones, including the resubmission of a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, and entering a licensing agreement with Zambon Biotech for IPX203 in Europe. The company also launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, underscoring their commitment to oncology treatment advancements.

Amneal's financial performance remains robust, with net revenue of $2.39 billion in 2023 and a strategic focus on expanding its reach through innovative products and international partnerships. The company continuously invests in research and development to meet the growing demands for affordable and high-quality medications, solidifying its position as a key player in the pharmaceutical industry. For more information, please visit www.amneal.com.

News

Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

Rhea-AI Summary
Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined Healthcare Innovation Catalysts, Inc. (HIC) as its first Chief Executive Officer. With over 30 years of experience in government and regulated industries, Ms. Autor brings expertise in regulatory, quality, compliance, business strategy, policy, and law. Her appointment is expected to further HIC's role as a sought-after advisor to global life sciences organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
-
News

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) will release its Q4 and full year 2023 financial results on March 1, 2024. A conference call and webcast will be held at 8:30 a.m. ET. The financial results and webcast will be accessible through the Investor Relations section of the Company's website. Participants can register for the conference call and receive dial-in details. A replay of the call will be available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences earnings
-
News

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) has received approval and launched fluorometholone ophthalmic suspension, USP, 0.1%, with 180-day competitive generic therapy exclusivity from the FDA. The product is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. The company aims to drive continued growth with the launch of this high-value product in the less crowded and durable ophthalmic category. Adverse effects include short-term inflammatory eye reactions and long-term use effects such as elevation of intraocular pressure and possible development of glaucoma, optic nerve damage, cataract formation, vision problems, and delayed eye wound healing. The U.S. annual sales for FML for the 12 months ended November 2023 were approximately $62 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
News

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) has announced the launch of 39 new retail and injectable medicines in 2023, compared to 26 in 2022. In the fourth quarter of 2023, 13 new products were launched, including 5 injectables. These launches are expected to drive higher injectable revenues in the future, with key new retail products such as spironolactone suspension and icosapent capsules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
earnings
-
News

Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. Chirag Patel and Tasos Konidaris to present on January 10th. Webcast accessible on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
conferences
-
News

Amneal Announces Move to Nasdaq

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will transfer its stock exchange listing to the Nasdaq Stock Market on December 27, 2023. The company will continue to trade under the symbol 'AMRX' and will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
News

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and BIAL - Portela & Ca., S.A. announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023. ONGENTYS® is a proprietary once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor), approved by the U.S. Food and Drug Administration in 2020 as an add-on treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson’s disease experiencing “Off” episodes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
News

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) partners with Strides Pharma Science Limited to commercialize Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product, in-licensed from Strides, will be launched in the fourth quarter of 2023. Icosapent ethyl is indicated to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Amneal plans to launch over 40 new products in 2023, including Icosapent ethyl, as part of their portfolio expansion strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.12%
Tags
none
-
News

Amneal Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) reported a net revenue of $620 million, GAAP net income of $10 million, and diluted EPS of $0.06 for Q3 2023. Adjusted net income was $60 million, Adjusted EBITDA was $154 million, and Adjusted Diluted EPS was $0.19. The company affirmed its 2023 full-year guidance, projecting net revenue of $2.37 billion to $2.42 billion, adjusted EBITDA of $540 million to $550 million, and adjusted diluted EPS of $0.51 to $0.58.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
earnings
News

Amneal to Participate at Upcoming Investor Conferences

Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will participate in investor conferences, including Jefferies 14th Annual Global Healthcare Conference on November 14, 2023, in London, UK, and Piper Sandler 35th Annual Healthcare Conference on November 28, 2023, in New York, New York. The presentations will be available via live webcast on the company's Investor Relations section of the website, with a replay available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences

FAQ

What is the current stock price of Amneal Pharmaceuticals (AMRX)?

The current stock price of Amneal Pharmaceuticals (AMRX) is $7.78 as of December 20, 2024.

What is the market cap of Amneal Pharmaceuticals (AMRX)?

The market cap of Amneal Pharmaceuticals (AMRX) is approximately 2.4B.

What does Amneal Pharmaceuticals, Inc. specialize in?

Amneal Pharmaceuticals specializes in developing, manufacturing, and distributing a wide range of generic and specialty pharmaceutical products.

What are the key segments of Amneal Pharmaceuticals?

Amneal operates through three segments: Generics, Specialty, and AvKARE. The Generics segment focuses on a broad range of dosage forms and delivery systems, Specialty targets central nervous system and endocrine disorders, and AvKARE distributes pharmaceuticals to governmental agencies.

Where is Amneal Pharmaceuticals headquartered?

Amneal Pharmaceuticals is headquartered in Bridgewater, NJ, USA.

What recent product has Amneal Pharmaceuticals launched in the oncology space?

Amneal recently launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, catering to oncology treatments.

What is the significance of Amneal's IPX203?

IPX203 is a novel oral formulation for the treatment of Parkinson’s disease. Amneal has resubmitted a Complete Response to the FDA and entered a licensing agreement with Zambon Biotech for its commercialization in Europe.

How does Amneal Pharmaceuticals contribute to the U.S. pharmaceutical market?

Amneal contributes by addressing chronic market shortages, particularly in the injectables category, and providing high-quality, affordable medicines through its expanded manufacturing capabilities.

What financial performance did Amneal achieve in 2023?

In 2023, Amneal reported a net revenue of $2.39 billion and continues to show robust financial health and growth prospects.

How is Amneal addressing the opioid crisis?

Amneal launched an Over the Counter Naloxone Hydrochloride Nasal Spray to help treat opioid overdoses, significantly expanding access to life-saving medication.

What are some key partnerships of Amneal Pharmaceuticals?

Amneal has partnered with Zambon Biotech for the commercialization of IPX203 in Europe and has also entered a distribution agreement with California for the supply of Naloxone HCI Nasal Spray.

How can investors get more information about Amneal Pharmaceuticals?

Investors can visit Amneal’s official website at www.amneal.com for detailed information and latest updates.

Stock AMRX logo
Amneal Pharmaceuticals, Inc.

Nasdaq:AMRX

AMRX Rankings

#1836 Ranked by Market Cap
N/A Ranked by Dividends

AMRX Stock Data

2.40B
135.66M
52.19%
46.48%
1.45%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
Bridgewater